Hypha Labs AI Stock Analysis
Want to see FUNI full AI Analyst Report?
Hypha Labs (FUNI) AI Stock Analysis
Hypha Labs
(Other OTC:FUNI)
FUNI presents extreme investment risk. The company's complete lack of revenue, mounting losses (-$2.28M TTM), and negative equity (-$2.35M) demonstrate operational failure with no viable business model. Technical charts confirm severe downtrend with bearish momentum indicators, while the negative P/E ratio precludes standard valuation analysis. Ongoing cash burn (-$522k TTM) threatens solvency without immediate restructuring or capital infusion. This is a distressed micro-cap with minimal recovery prospects in its competitive sector.
Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $327.79K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.15
- Revenue Growth
- ―
- EPS Growth
- 47.23%
- Country
- US
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Hypha Labs Business Overview & Revenue Model
Company Description
Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate benef...
How the Company Makes Money
null
Hypha Labs Financial Statement Overview
Summary
Severe financial distress with zero revenue across all periods, escalating net losses from -$785k (2024) to -$2.28M (TTM), and negative stockholders' equity of -$2.35M (TTM). Persistent cash burn and declining assets indicate fundamental operational failure in a competitive sector.
Income Statement
12Very NegativeBalance Sheet
8Very NegativeCash Flow
25Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.70M | 2.50M |
| Gross Profit | -23.96K | 0 | 0 | 0 | 1.07M | 715.16K |
| EBITDA | -1.47M | -2.95M | -1.37M | -58.24K | -1.73M | -249.00K |
| Net Income | -1.91M | -3.10M | -785.00K | 246.77K | -2.06M | -687.00K |
Balance Sheet | ||||||
| Total Assets | 68.33K | 409.22K | 493.81K | 1.41M | 1.34M | 1.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5,110 | 38.12K | 91.17K | 271.01K | 56.17K | 295.93K |
| Total Debt | 1.79M | 1.65M | 1.14M | 2.29M | 2.35M | 2.79M |
| Total Liabilities | 3.16M | 2.51M | 1.42M | 3.28M | 4.08M | 2.94M |
| Stockholders Equity | -3.09M | -2.10M | -926.69K | -1.87M | -2.41M | -1.05M |
Cash Flow | ||||||
| Free Cash Flow | -599.29K | -412.94K | -1.42M | 112.52K | -202.51K | -192.17K |
| Operating Cash Flow | -568.05K | -379.98K | -1.39M | 112.53K | -184.79K | -135.97K |
| Investing Cash Flow | -31.24K | -32.97K | 2.15M | 263.33K | -660.37K | -286.21K |
| Financing Cash Flow | 457.21K | 359.89K | -1.28M | -161.02K | 605.39K | 635.36K |
Hypha Labs Risk Analysis
Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHypha Labs Peers Comparison
Overall Rating
PRPO65Neutral
BIAF43Neutral
INBS41Neutral
TRIB41Neutral
ISPC40Underperform
FUNI23Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $34.37M | -31.03 | -7.84% | ― | 21.76% | 22.97% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $3.51M | -0.04 | -331.02% | ― | -18.47% | 87.82% | |
| 41Neutral | $5.11M | -0.23 | -146.09% | ― | 36.55% | 60.09% | |
| 41Neutral | $3.75M | -0.13 | 48.72% | ― | -13.28% | 39.65% | |
| 40Underperform | $3.09M | -0.02 | -447.15% | ― | -81.99% | 89.77% | |
| 23Underperform | $327.79K | -0.16 | 73.84% | ― | ― | 47.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FUNI | Hypha Labs, Inc. | 0.01 | -0.01 | -57.69% | |
| TRIB | Trinity Biotech | 5.83 | -19.21 | -76.73% | |
| PRPO | Precipio | 18.76 | -6.86 | -26.78% | |
| INBS | Intelligent Bio Solutions Inc. | 1.54 | -4.88 | -76.01% | |
| ISPC | Ispecimen Inc | 0.53 | -16.31 | -96.83% | |
| BIAF | bioAffinity Technologies, Inc. | 2.15 | -18.55 | -89.61% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 18, 2026
